Pulmonx’s AeriSeal Device Used to Treat First Patient

Pulmonx, who specialise in providing minimally invasive solutions for the treatment of chronic obstructive pulmonary disease, has treated their first patient in the second stage study of the AeriSeal device. 

This investigation will be analysing AeriSeal system’s capacity to restrict collateral ventilation in patients with severe respiratory conditions and potentially expanding the cohort eligible for Zephyr valves, another method for minimally invasive intervention. 

Following the investigational device exemption approval from the US FDA, the study seeks to validate the risks and effectiveness associated with the AeriSeal System. 

The research’s benchmarks for success encompass reductions in lung volume and enhancements in lung function and quality of life. This will be evaluated for six months following the treatment. 

Glen French, the leading officer of Pulmonx, commented, “We hope the CONVERT II Trial will move us closer to the goal of helping patients with collateral ventilation to also receive benefit from our Zephyr valves.” 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.